Core Viewpoint - The company Jabiou has decided to terminate its acquisition plan for a stake in Ouyi Biotechnology due to changes in the external market environment and after thorough communication with relevant parties [2][3]. Group 1: Acquisition Plan - Jabiou initially planned to acquire 63.21% of Ouyi Biotechnology's shares for approximately 831 million yuan, while also issuing shares to raise matching funds from no more than 35 specific investors [2]. - The acquisition was notable due to an asset appraisal increase of 441.23%, which would have resulted in a goodwill increase of 721 million yuan for Jabiou [2]. - The acquisition plan underwent several adjustments, including a reduction in the stake from 65% to 63.21% and changes in the performance compensation calculation method [2][3]. Group 2: Business Operations - Despite the termination of the acquisition, Jabiou stated that its business operations remain normal and that the decision will not adversely affect daily operations or harm the interests of shareholders, particularly minority shareholders [3]. - The company continues to focus on its strategic goals and aims to enhance its synthetic biology technology system, including omics technology [3]. - In the first half of the year, Jabiou reported a revenue of 307 million yuan, representing a year-on-year growth of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a 59.01% increase [3].

泰林生物: 国浩律师（杭州）事务所关于浙江泰林 生物技术股份有限公司2025年员工持股计划之法律 意见书 国浩律师（杭州）事务所 关 于 浙江泰林生物技术股份有限公司 之 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师 楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年三月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关于浙江泰林生物技术股份有限公司 法律意见书 致：浙江泰林生物技术股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江泰林生物技术股份有 限公司（以下简称"公司"、"发行人"或"泰林生物" ...